perineural dexmedetomidine — Competitive Intelligence Brief

perineural dexmedetomidine (perineural dexmedetomidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Anesthesia/Pain Management.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Anesthesia/Pain Management Small molecule

Target snapshot

perineural dexmedetomidine (perineural dexmedetomidine) — Guangzhou Women and Children's Medical Center. Perineural dexmedetomidine is an alpha-2 adrenergic agonist administered around nerves to provide prolonged local anesthesia and analgesia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
perineural dexmedetomidine TARGET	perineural dexmedetomidine	Guangzhou Women and Children's Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Precedex (Dexmedetomidine)	Precedex (Dexmedetomidine)	Icahn School of Medicine at Mount Sinai	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Dexmetomidine intravenously	Dexmetomidine intravenously	KAT General Hospital	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
dexmedetomidine 2	dexmedetomidine 2	National Cancer Institute, Egypt	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
fentanyl and dexmedetomindine	fentanyl and dexmedetomindine	The Affiliated Hospital of Qingdao University	marketed	Opioid agonist combined with alpha-2 adrenergic agonist	Mu opioid receptor (fentanyl); Alpha-2 adrenergic receptor (dexmedetomidine)
Dexmedetomidine-esketamine combination	Dexmedetomidine-esketamine combination	Peking University First Hospital	marketed	Sedative-analgesic combination	Alpha-2 adrenergic receptor; NMDA receptor
ropivacaine mixed with dexmedetomidine	ropivacaine mixed with dexmedetomidine	The First Hospital of Qinhuangdao	marketed	Local anesthetic combination with alpha-2 adrenergic agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

1. USWM, LLC (dba US WorldMeds) · 2 drugs in this class
2. China International Neuroscience Institution · 1 drug in this class
3. Icahn School of Medicine at Mount Sinai · 1 drug in this class
4. Eye Therapies, LLC · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Guangzhou Women and Children's Medical Center · 1 drug in this class
7. Derm Research, PLLC · 1 drug in this class
8. Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
9. KK Women's and Children's Hospital · 1 drug in this class
10. American University of Beirut Medical Center · 1 drug in this class